Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Date：2016-02-05Source: AmoyDx
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection kit: EGFR/ALK/ROS1 panel detecting 18 EGFR mutations, 5 ALK fusions and 9 ROS1 fusions simultaneously. The highly sensitive assay uses one step real-time PCR (combined reverse transcription and PCR amplification technology) to analyze EGFR, ALK, and ROS1 gene status in human NSCLC (non-small cell lung cancer) tissue samples. The kit also got CE-mark in Europe.
Recommend
Visit AmoyDx at 2022 ASCO Annual Meeting in Chicago, IL, USA
05 /05
Filing Notice for a Manufacturing and Marketing Application for AmoyDx® Pan Lung Cancer PCR Panel as a Companion Diagnostic for a Drug Targeting RET fusion-Positive Non-Small Cell Lung Cancer
20 /04
AmoyDx Enters into Master Collaboration Agreement with AstraZeneca for Multiple Companion Diagnostics Programs in China, EU and Japan
18 /04
Beckman Coulter Life Sciences and Amoy Diagnostics Sign Application Development Agreement for the Biomek Ngenius Next Generation Library Prep System
13 /04
AmoyDx Signs Strategic Cooperation Agreement with HUTCHMED in China
08 /04